Related Experiment Video
Updated: Sep 27, 2026
Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
Published on: February 20, 2015
Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer
Shigenori Kanazawa1, Shosaku Nomura, Midori Kuwana
1The First Department of Internal Medicine, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka 570-8507, Japan.
Abstract:
We measured and compared the levels of plasma monocyte-derived microparticles (MDMP) and platelet activation markers [plasma platelet-derived microparticles (PDMP), CD62P binding to platelets; plt-CD62P, CD63 binding to platelets; plt-CD63], to develop a better understanding of their potential contribution to vascular complications of lung cancer. The concentrations of MDMP and PDMP in lung cancer patients were significantly higher (P < 0.01) than those in normal subjects. Levels of plt-CD62P and plt-CD63 were significantly higher (P < 0.001 for each) in lung cancer patients than in controls. Levels of sE-selectin were also higher in lung cancer patients than in control subjects. MDMP correlated positively with plt-CD62P, plt-CD63, and PDMP with its relation to PDMP being particularly significant. The number of MDMPs and PDMPs are patients who are non-small cell lung cancer were significantly higher than that in small cell lung cancer patients. In addition, levels of sE-selectin were higher in non-small cell lung cancer than in small cell lung cancer patients. These findings suggest that elevated MDMPs may be a sign of vascular complication in lung cancer patients, particularly those who suffer from non-small cell lung cancer.
Insights
Elevated levels of monocyte-derived microparticles (MDMP) and platelet activation markers are significantly higher in lung cancer patients, indicating potential vascular complications, especially in non-small cell lung cancer.
Area of Science:
- Oncology
- Hematology
- Vascular Biology
Background:
- Lung cancer is associated with an increased risk of vascular complications.
- Microparticles and platelet activation markers are implicated in thrombotic events.
Purpose of the Study:
- To investigate plasma monocyte-derived microparticles (MDMP) and platelet activation markers in lung cancer patients.
- To determine the association of these markers with vascular complications in lung cancer.
Main Methods:
- Quantification of plasma MDMP and plasma platelet-derived microparticles (PDMP).
- Measurement of platelet-bound CD62P (plt-CD62P) and CD63 (plt-CD63) expression.
- Comparison of marker levels between lung cancer patients and healthy controls.
- Analysis of marker levels in non-small cell lung cancer (NSCLC) versus small cell lung cancer (SCLC) subtypes.
Main Results:
- MDMP and PDMP levels were significantly elevated in lung cancer patients compared to controls (P < 0.01).
- Platelet activation markers (plt-CD62P, plt-CD63) and sE-selectin were significantly higher in lung cancer patients (P < 0.001).
- MDMP showed positive correlations with plt-CD62P, plt-CD63, and PDMP.
- Elevated MDMP, PDMP, and sE-selectin levels were more pronounced in NSCLC patients than in SCLC patients.
Conclusions:
- Elevated plasma MDMP levels may serve as a biomarker for vascular complications in lung cancer.
- Non-small cell lung cancer is associated with higher levels of MDMP and PDMP compared to small cell lung cancer.
- These findings highlight the role of microparticles and platelet activation in lung cancer-related vascular pathology.
